Santen Proposes General Reserve Reversal for Shareholder Stability

Santen Pharmaceutical Co ( (JP:4536) ) has issued an update.

Santen Pharmaceutical Co., Ltd. announced a proposal to reverse its general reserve by transferring JPY 50.0 billion to retained earnings, aimed at ensuring stable shareholder returns. This accounting adjustment, pending approval at the upcoming Annual General Meeting, will not impact the company’s profit and loss as it involves a reallocation within net assets, leaving the total net asset unchanged.

The most recent analyst rating on (JP:4536) stock is a Buy with a Yen1900.00 price target. To see the full list of analyst forecasts on Santen Pharmaceutical Co stock, see the JP:4536 Stock Forecast page.

More about Santen Pharmaceutical Co

Santen Pharmaceutical Co., Ltd. is a specialized company dedicated to eye health, providing products and services to patients, consumers, and medical professionals globally. With over 130 years of experience, Santen focuses on the research, development, manufacturing, and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people across more than 60 countries. The company’s mission is to offer significant value in the prevention, diagnosis, and treatment of eye diseases, aiming to help people lead happy and fulfilling lives through improved vision.

Average Trading Volume: 1,229,031

Technical Sentiment Signal: Hold

Current Market Cap: Yen499.5B

For detailed information about 4536 stock, go to TipRanks’ Stock Analysis page.